|
|
|
||||||||||
Assistant Chair of Pharmacology Department of Experimental and Clinical Medicine Faculty of Medicine and Surgery University Magna Graecia of Catanzaro Regional Pharmacovigilance Center Mater Domini University Hospital Via T. Campanella 115 88100 Catanzaro, Italy fax 39-0-961-774424 luca_gallelli{at}hotmail.com
Full Professor Chair of Infectious Diseases Department of Experimental and Clinical Medicine Faculty of Medicine and Surgery University of Catanzaro
Clinical Specialist Chair of Infectious Diseases Department of Experimental and Clinical Medicine Faculty of Medicine and Surgery University of Catanzaro
Assistant Chair of Pharmacology Department of Experimental and Clinical Medicine Faculty of Medicine and Surgery University Magna Graecia of Catanzaro Regional Pharmacovigilance Center Mater Domini University Hospital
Full Professor Chair of Pharmacology Department of Experimental and Clinical Medicine Faculty of Medicine and Surgery University Magna Graecia of Catanzaro Regional Pharmacovigilance Center Mater Domini University Hospital
Published Online, December 5, 2003. www.theannals.com, DOI 10.1345/aph.1D198
Case Report. A 56-year-old man with chronic hepatitis C infection presented with cutaneous ulcerations and a high antinuclear antibody (ANA) titer 7 months after initiation of pegylated INF-alfa treatment. Change of injection site and topical treatment did not stop these skin lesions. Therefore, 3 months later, pegylated INF-alfa therapy was discontinued due to a relevant increase in ANA titer (Table 1) and a progression of cutaneous lesions.
|
Tests for other autoimmune serologic manifestations (antimicrosomal antibody, antismooth-muscle antibodies, liverkidney microsomal antibodies, thyroid peroxidase antibodies, antidouble-stranded DNA) and for total and differential circulating immunoglobulins (Igs) were negative. Histologic examination of skin lesions revealed perivascular infiltration of lymphoid cells of the upper derma without an increase of Ig blood values, suggesting a nonallergic mechanism for these manifestations.
Two months after pegylated INF-alfa therapy interruption, a new evaluation showed a significant decrease in transaminase values (Table 1) and a partial remission of cutaneous ulcers. During follow-up performed 12 months later, we recorded a complete remission of skin manifestations and a complete reduction in ANA titer (Table 1). Use of the Naranjo probability scale indicated a probable relationship between the bilateral skin eruption and pegylated INF therapy in our patient.5
We conclude that an INF-associated immunologic mechanism is involved in skin ulcer manifestations that could be relevant in the future setting of therapy.
References
This article has been cited by other articles:
![]() |
L. Gallelli, M. Ferraro, G. F Mauro, and G. De Sarro Generalized exfoliative dermatitis induced by interferon alfa Ann. Pharmacother., December 1, 2004; 38(12): 2173 - 2174. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||